Pulmatrix Net Income vs. Return On Equity
Earnings Share -1.41 | Revenue Per Share | Quarterly Revenue Growth -1.00 | Return On Assets | Return On Equity |
Market capitalization and book value offer complementary views of Pulmatrix - the first driven by investor sentiment, the second by accounting standards. Pulmatrix's market capitalization is 7.71 M. A P/B ratio of 1.99 indicates the market values Pulmatrix above its accounting book value. Value and price for Pulmatrix are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
Note that Pulmatrix's intrinsic value and market price are different measures derived from different inputs. For Pulmatrix, key inputs include a P/B ratio of 1.99, and ROE of -80.93%. Pulmatrix's trading price represents the transaction level agreed by market participants.
Pulmatrix Return On Equity vs. Net Income Fundamental Analysis
Multiples-driven valuation compares Pulmatrix across sector performance standards. Pulmatrix lands at #3 in net income compared to key competitors. It lands at #2 in return on equity compared to key competitors . Pulmatrix’s Net Loss is trending toward -5.42 Million, a 4.76% year-over-year shift. In the prior fiscal year, Net Loss was reported at -5.16 Million. Earnings multiples remain central to Pulmatrix's valuation analysis.Pulmatrix Return On Equity vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Pulmatrix |
| = | -5.16 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Return on Equity (ROE) measures how effectively a company converts shareholders' equity into net income. It is calculated by dividing net income by average shareholders' equity, and it reflects management's ability to generate profit from the capital investors have committed. ROE is one of the most widely used profitability ratios because it ties directly to shareholder value creation.
Pulmatrix |
| = | -0.81 |
An ROE between 10% and 30% is generally considered healthy for most industries, supporting both dividend payments and reinvestment in future growth. However, ROE should not be evaluated in isolation. A high ROE driven by excessive financial leverage can signal risk rather than efficiency, so investors typically cross-reference ROE with debt-to-equity ratios and return on assets to distinguish genuine operational strength from balance-sheet amplification.
Pulmatrix Return On Equity Comparison
Pulmatrix is currently under evaluation in return on equity compared to key competitors.
Pulmatrix Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Pulmatrix, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pulmatrix will eventually generate negative long term returns. The profitability progress is the general direction of Pulmatrix's change in net profit over the period of time. It can combine multiple indicators of Pulmatrix, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -1.9 M | -2 M | |
| Operating Income | -5.2 M | -5.4 M | |
| Income Before Tax | -5.2 M | -5.4 M | |
| Net Loss | -5.2 M | -5.4 M | |
| Total Other Income Expense Net | 7 K | 7.3 K | |
| Income Tax Expense | -11 M | -10.4 M | |
| Net Loss | -5.2 M | -5.4 M | |
| Non Operating Income Net Other | -8.5 M | -8.1 M | |
| Net Loss | -17 M | -17.8 M | |
| Interest Income | 144 K | 136.8 K | |
| Net Interest Income | 144 K | 151.2 K | |
| Change To Netincome | 1 M | 952.5 K | |
| Net Loss | -1.41 | -1.48 | |
| Income Quality | 1.05 | 0.62 | |
| Net Income Per E B T | 0.81 | 0.72 |
Pulmatrix Profitability Driver Comparison
Investors in Pulmatrix should monitor its profitability drivers closely, as these factors directly influence long-term investment value. Unexpected events - from macroeconomic disruptions to industry shocks - can significantly alter Pulmatrix's earnings outlook and broader investment thesis.
Earnings per Share Projection vs Actual
Use Pulmatrix in pair-trading
Pair analysis around Pulmatrix matters because it can turn one security idea into a more market-neutral structure. The advantage is that adverse movement in one leg may be partly offset by the other when correlation and thesis alignment hold.
Pulmatrix Pair Trading
Pulmatrix Pair Trading Analysis
The effectiveness of tax-loss harvesting on Pulmatrix depends on finding a suitable replacement asset. Instruments with correlation above 0.9 to Pulmatrix typically provide adequate market exposure during the required holding period.
Interpreting the correlation table for Pulmatrix: readings above 0.8 indicate strongly correlated pairs with minimal diversification benefit, while readings between -0.2 and +0.2 around Pulmatrix suggest near-independence and genuine portfolio diversification value.
Use Correlation analysis and pair trading evaluation for Pulmatrix to review hedging context. The context can be applied within sectors, industries, or broader universes.Use Investing Themes to Complement your Pulmatrix position
At 7.71 Million in the Biotechnology space, Pulmatrix smaller-cap profile gives investors a structured starting point for building sector-aligned themes. Building a Healthcare theme from Pulmatrix 7.71 Million position turns a single Biotechnology conviction into a risk-managed basket.
Did You Try This Idea?
Run Marketing Thematic Idea Now
Marketing
Companies providing marketing and public relation (PR) services as well as news and media distribution. The Marketing theme has 46 constituents at this time.
Whether used as a passive allocation or an active trading idea, the Marketing Theme provides a structured starting point for portfolio construction.
| View All Next | Launch |
More Resources for Pulmatrix Stock Analysis
A structured review of Pulmatrix often starts with core financial statements and trend context. Financial ratios provide a structured lens for assessing Pulmatrix's profitability and growth trends. Below are reports that help frame Pulmatrix Stock in context:Your Equity Center. Our How to Invest in Pulmatrix guide provides practical guidance on trading Pulmatrix Stock.Pulmatrix currently shows ROE of -80.93%, market cap of 7.71 Million. Pulmatrix analysis should be paired with portfolio risk and diversification tools before adjusting allocations. Pulmatrix analysis across multiple dimensions - risk, valuation, diversification - produces a more informed position-sizing decision. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Projecting Pulmatrix's profitability starts with historical financial statements. The core view includes income statement, balance sheet, and cash flow.